Global Systemic Scleroderma Treatment Supply, Demand and Key Producers, 2024-2030

Description

The global Systemic Scleroderma Treatment market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Systemic scleroderma is an autoimmune disorder that affects the skin and internal organs . It is characterized by the buildup of scar tissue (fibrosis) in the skin and other organs. The fibrosis is caused by the body's production of too much collagen, which normally strengthens and supports connective tissues.

This report studies the global Systemic Scleroderma Treatment demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Systemic Scleroderma Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Systemic Scleroderma Treatment that contribute to its increasing demand across many markets.

Highlights and key features of the study
Global Systemic Scleroderma Treatment total market, 2019-2030, (USD Million)
Global Systemic Scleroderma Treatment total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Systemic Scleroderma Treatment total market, key domestic companies and share, (USD Million)
Global Systemic Scleroderma Treatment revenue by player and market share 2019-2024, (USD Million)
Global Systemic Scleroderma Treatment total market by Type, CAGR, 2019-2030, (USD Million)
Global Systemic Scleroderma Treatment total market by Application, CAGR, 2019-2030, (USD Million).

This reports profiles major players in the global Systemic Scleroderma Treatment market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boehringer Ingelheim International GmbH, Gilead Sciences Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc. and Bayer AG, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Systemic Scleroderma Treatment market.

Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Systemic Scleroderma Treatment Market, By Region:
    United States
    China
    Europe
    Japan
    South Korea
    ASEAN
    India
    Rest of World

Global Systemic Scleroderma Treatment Market, Segmentation by Type
    Immunosuppressors
    Phosphodiesterase 5 inhibitors - PHA
    Endothelin Receptor Antagonists
    Prostacyclin Analogues
    Calcium Channel Blockers
    Others

Global Systemic Scleroderma Treatment Market, Segmentation by Application
    Hospital
    Clinics
    Others

Companies Profiled:
    Boehringer Ingelheim International GmbH
    Gilead Sciences Inc.
    GlaxoSmithKline plc
    Novartis AG
    Pfizer Inc.
    Bayer AG

Key Questions Answered
1. How big is the global Systemic Scleroderma Treatment market?
2. What is the demand of the global Systemic Scleroderma Treatment market?
3. What is the year over year growth of the global Systemic Scleroderma Treatment market?
4. What is the total value of the global Systemic Scleroderma Treatment market?
5. Who are the major players in the global Systemic Scleroderma Treatment market?

Table of Contents

1 Supply Summary
    1.1 Systemic Scleroderma Treatment Introduction
    1.2 World Systemic Scleroderma Treatment Market Size & Forecast (2019 & 2023 & 2030)
    1.3 World Systemic Scleroderma Treatment Total Market by Region (by Headquarter Location)
        1.3.1 World Systemic Scleroderma Treatment Market Size by Region (2019-2030), (by Headquarter Location)
        1.3.2 United States Systemic Scleroderma Treatment Market Size (2019-2030)
        1.3.3 China Systemic Scleroderma Treatment Market Size (2019-2030)
        1.3.4 Europe Systemic Scleroderma Treatment Market Size (2019-2030)
        1.3.5 Japan Systemic Scleroderma Treatment Market Size (2019-2030)
        1.3.6 South Korea Systemic Scleroderma Treatment Market Size (2019-2030)
        1.3.7 ASEAN Systemic Scleroderma Treatment Market Size (2019-2030)
        1.3.8 India Systemic Scleroderma Treatment Market Size (2019-2030)
    1.4 Market Drivers, Restraints and Trends
        1.4.1 Systemic Scleroderma Treatment Market Drivers
        1.4.2 Factors Affecting Demand
        1.4.3 Systemic Scleroderma Treatment Major Market Trends

2 Demand Summary
    2.1 World Systemic Scleroderma Treatment Consumption Value (2019-2030)
    2.2 World Systemic Scleroderma Treatment Consumption Value by Region
        2.2.1 World Systemic Scleroderma Treatment Consumption Value by Region (2019-2024)
        2.2.2 World Systemic Scleroderma Treatment Consumption Value Forecast by Region (2025-2030)
    2.3 United States Systemic Scleroderma Treatment Consumption Value (2019-2030)
    2.4 China Systemic Scleroderma Treatment Consumption Value (2019-2030)
    2.5 Europe Systemic Scleroderma Treatment Consumption Value (2019-2030)
    2.6 Japan Systemic Scleroderma Treatment Consumption Value (2019-2030)
    2.7 South Korea Systemic Scleroderma Treatment Consumption Value (2019-2030)
    2.8 ASEAN Systemic Scleroderma Treatment Consumption Value (2019-2030)
    2.9 India Systemic Scleroderma Treatment Consumption Value (2019-2030)

3 World Systemic Scleroderma Treatment Companies Competitive Analysis
    3.1 World Systemic Scleroderma Treatment Revenue by Player (2019-2024)
    3.2 Industry Rank and Concentration Rate (CR)
        3.2.1 Global Systemic Scleroderma Treatment Industry Rank of Major Players
        3.2.2 Global Concentration Ratios (CR4) for Systemic Scleroderma Treatment in 2023
        3.2.3 Global Concentration Ratios (CR8) for Systemic Scleroderma Treatment in 2023
    3.3 Systemic Scleroderma Treatment Company Evaluation Quadrant
    3.4 Systemic Scleroderma Treatment Market: Overall Company Footprint Analysis
        3.4.1 Systemic Scleroderma Treatment Market: Region Footprint
        3.4.2 Systemic Scleroderma Treatment Market: Company Product Type Footprint
        3.4.3 Systemic Scleroderma Treatment Market: Company Product Application Footprint
    3.5 Competitive Environment
        3.5.1 Historical Structure of the Industry
        3.5.2 Barriers of Market Entry
        3.5.3 Factors of Competition
    3.6 Mergers, Acquisitions Activity

4 United States VS China VS Rest of the World (by Headquarter Location)
    4.1 United States VS China: Systemic Scleroderma Treatment Revenue Comparison (by Headquarter Location)
        4.1.1 United States VS China: Systemic Scleroderma Treatment Market Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
        4.1.2 United States VS China: Systemic Scleroderma Treatment Revenue Market Share Comparison (2019 & 2023 & 2030)
    4.2 United States Based Companies VS China Based Companies: Systemic Scleroderma Treatment Consumption Value Comparison
        4.2.1 United States VS China: Systemic Scleroderma Treatment Consumption Value Comparison (2019 & 2023 & 2030)
        4.2.2 United States VS China: Systemic Scleroderma Treatment Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    4.3 United States Based Systemic Scleroderma Treatment Companies and Market Share, 2019-2024
        4.3.1 United States Based Systemic Scleroderma Treatment Companies, Headquarters (States, Country)
        4.3.2 United States Based Companies Systemic Scleroderma Treatment Revenue, (2019-2024)
    4.4 China Based Companies Systemic Scleroderma Treatment Revenue and Market Share, 2019-2024
        4.4.1 China Based Systemic Scleroderma Treatment Companies, Company Headquarters (Province, Country)
        4.4.2 China Based Companies Systemic Scleroderma Treatment Revenue, (2019-2024)
    4.5 Rest of World Based Systemic Scleroderma Treatment Companies and Market Share, 2019-2024
        4.5.1 Rest of World Based Systemic Scleroderma Treatment Companies, Headquarters (States, Country)
        4.5.2 Rest of World Based Companies Systemic Scleroderma Treatment Revenue, (2019-2024)

5 Market Analysis by Type
    5.1 World Systemic Scleroderma Treatment Market Size Overview by Type: 2019 VS 2023 VS 2030
    5.2 Segment Introduction by Type
        5.2.1 Immunosuppressors
        5.2.2 Phosphodiesterase 5 inhibitors - PHA
        5.2.3 Endothelin Receptor Antagonists
        5.2.4 Prostacyclin Analogues
        5.2.5 Calcium Channel Blockers
        5.2.6 Others
    5.3 Market Segment by Type
        5.3.1 World Systemic Scleroderma Treatment Market Size by Type (2019-2024)
        5.3.2 World Systemic Scleroderma Treatment Market Size by Type (2025-2030)
        5.3.3 World Systemic Scleroderma Treatment Market Size Market Share by Type (2019-2030)

6 Market Analysis by Application
    6.1 World Systemic Scleroderma Treatment Market Size Overview by Application: 2019 VS 2023 VS 2030
    6.2 Segment Introduction by Application
        6.2.1 Hospital
        6.2.2 Clinics
        6.2.3 Others
    6.3 Market Segment by Application
        6.3.1 World Systemic Scleroderma Treatment Market Size by Application (2019-2024)
        6.3.2 World Systemic Scleroderma Treatment Market Size by Application (2025-2030)
        6.3.3 World Systemic Scleroderma Treatment Market Size by Application (2019-2030)

7 Company Profiles
    7.1 Boehringer Ingelheim International GmbH
        7.1.1 Boehringer Ingelheim International GmbH Details
        7.1.2 Boehringer Ingelheim International GmbH Major Business
        7.1.3 Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Product and Services
        7.1.4 Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.1.5 Boehringer Ingelheim International GmbH Recent Developments/Updates
        7.1.6 Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
    7.2 Gilead Sciences Inc.
        7.2.1 Gilead Sciences Inc. Details
        7.2.2 Gilead Sciences Inc. Major Business
        7.2.3 Gilead Sciences Inc. Systemic Scleroderma Treatment Product and Services
        7.2.4 Gilead Sciences Inc. Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.2.5 Gilead Sciences Inc. Recent Developments/Updates
        7.2.6 Gilead Sciences Inc. Competitive Strengths & Weaknesses
    7.3 GlaxoSmithKline plc
        7.3.1 GlaxoSmithKline plc Details
        7.3.2 GlaxoSmithKline plc Major Business
        7.3.3 GlaxoSmithKline plc Systemic Scleroderma Treatment Product and Services
        7.3.4 GlaxoSmithKline plc Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.3.5 GlaxoSmithKline plc Recent Developments/Updates
        7.3.6 GlaxoSmithKline plc Competitive Strengths & Weaknesses
    7.4 Novartis AG
        7.4.1 Novartis AG Details
        7.4.2 Novartis AG Major Business
        7.4.3 Novartis AG Systemic Scleroderma Treatment Product and Services
        7.4.4 Novartis AG Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.4.5 Novartis AG Recent Developments/Updates
        7.4.6 Novartis AG Competitive Strengths & Weaknesses
    7.5 Pfizer Inc.
        7.5.1 Pfizer Inc. Details
        7.5.2 Pfizer Inc. Major Business
        7.5.3 Pfizer Inc. Systemic Scleroderma Treatment Product and Services
        7.5.4 Pfizer Inc. Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.5.5 Pfizer Inc. Recent Developments/Updates
        7.5.6 Pfizer Inc. Competitive Strengths & Weaknesses
    7.6 Bayer AG
        7.6.1 Bayer AG Details
        7.6.2 Bayer AG Major Business
        7.6.3 Bayer AG Systemic Scleroderma Treatment Product and Services
        7.6.4 Bayer AG Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024)
        7.6.5 Bayer AG Recent Developments/Updates
        7.6.6 Bayer AG Competitive Strengths & Weaknesses

8 Industry Chain Analysis
    8.1 Systemic Scleroderma Treatment Industry Chain
    8.2 Systemic Scleroderma Treatment Upstream Analysis
    8.3 Systemic Scleroderma Treatment Midstream Analysis
    8.4 Systemic Scleroderma Treatment Downstream Analysis

9 Research Findings and Conclusion

10 Appendix
    10.1 Methodology
    10.2 Research Process and Data Source
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. World Systemic Scleroderma Treatment Revenue by Region (2019, 2023 and 2030) & (USD Million), (by Headquarter Location)
    Table 2. World Systemic Scleroderma Treatment Revenue by Region (2019-2024) & (USD Million), (by Headquarter Location)
    Table 3. World Systemic Scleroderma Treatment Revenue by Region (2025-2030) & (USD Million), (by Headquarter Location)
    Table 4. World Systemic Scleroderma Treatment Revenue Market Share by Region (2019-2024), (by Headquarter Location)
    Table 5. World Systemic Scleroderma Treatment Revenue Market Share by Region (2025-2030), (by Headquarter Location)
    Table 6. Major Market Trends
    Table 7. World Systemic Scleroderma Treatment Consumption Value Growth Rate Forecast by Region (2019 & 2023 & 2030) & (USD Million)
    Table 8. World Systemic Scleroderma Treatment Consumption Value by Region (2019-2024) & (USD Million)
    Table 9. World Systemic Scleroderma Treatment Consumption Value Forecast by Region (2025-2030) & (USD Million)
    Table 10. World Systemic Scleroderma Treatment Revenue by Player (2019-2024) & (USD Million)
    Table 11. Revenue Market Share of Key Systemic Scleroderma Treatment Players in 2023
    Table 12. World Systemic Scleroderma Treatment Industry Rank of Major Player, Based on Revenue in 2023
    Table 13. Global Systemic Scleroderma Treatment Company Evaluation Quadrant
    Table 14. Head Office of Key Systemic Scleroderma Treatment Player
    Table 15. Systemic Scleroderma Treatment Market: Company Product Type Footprint
    Table 16. Systemic Scleroderma Treatment Market: Company Product Application Footprint
    Table 17. Systemic Scleroderma Treatment Mergers & Acquisitions Activity
    Table 18. United States VS China Systemic Scleroderma Treatment Market Size Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 19. United States VS China Systemic Scleroderma Treatment Consumption Value Comparison, (2019 & 2023 & 2030) & (USD Million)
    Table 20. United States Based Systemic Scleroderma Treatment Companies, Headquarters (States, Country)
    Table 21. United States Based Companies Systemic Scleroderma Treatment Revenue, (2019-2024) & (USD Million)
    Table 22. United States Based Companies Systemic Scleroderma Treatment Revenue Market Share (2019-2024)
    Table 23. China Based Systemic Scleroderma Treatment Companies, Headquarters (Province, Country)
    Table 24. China Based Companies Systemic Scleroderma Treatment Revenue, (2019-2024) & (USD Million)
    Table 25. China Based Companies Systemic Scleroderma Treatment Revenue Market Share (2019-2024)
    Table 26. Rest of World Based Systemic Scleroderma Treatment Companies, Headquarters (States, Country)
    Table 27. Rest of World Based Companies Systemic Scleroderma Treatment Revenue, (2019-2024) & (USD Million)
    Table 28. Rest of World Based Companies Systemic Scleroderma Treatment Revenue Market Share (2019-2024)
    Table 29. World Systemic Scleroderma Treatment Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Table 30. World Systemic Scleroderma Treatment Market Size by Type (2019-2024) & (USD Million)
    Table 31. World Systemic Scleroderma Treatment Market Size by Type (2025-2030) & (USD Million)
    Table 32. World Systemic Scleroderma Treatment Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Table 33. World Systemic Scleroderma Treatment Market Size by Application (2019-2024) & (USD Million)
    Table 34. World Systemic Scleroderma Treatment Market Size by Application (2025-2030) & (USD Million)
    Table 35. Boehringer Ingelheim International GmbH Basic Information, Area Served and Competitors
    Table 36. Boehringer Ingelheim International GmbH Major Business
    Table 37. Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Product and Services
    Table 38. Boehringer Ingelheim International GmbH Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 39. Boehringer Ingelheim International GmbH Recent Developments/Updates
    Table 40. Boehringer Ingelheim International GmbH Competitive Strengths & Weaknesses
    Table 41. Gilead Sciences Inc. Basic Information, Area Served and Competitors
    Table 42. Gilead Sciences Inc. Major Business
    Table 43. Gilead Sciences Inc. Systemic Scleroderma Treatment Product and Services
    Table 44. Gilead Sciences Inc. Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 45. Gilead Sciences Inc. Recent Developments/Updates
    Table 46. Gilead Sciences Inc. Competitive Strengths & Weaknesses
    Table 47. GlaxoSmithKline plc Basic Information, Area Served and Competitors
    Table 48. GlaxoSmithKline plc Major Business
    Table 49. GlaxoSmithKline plc Systemic Scleroderma Treatment Product and Services
    Table 50. GlaxoSmithKline plc Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 51. GlaxoSmithKline plc Recent Developments/Updates
    Table 52. GlaxoSmithKline plc Competitive Strengths & Weaknesses
    Table 53. Novartis AG Basic Information, Area Served and Competitors
    Table 54. Novartis AG Major Business
    Table 55. Novartis AG Systemic Scleroderma Treatment Product and Services
    Table 56. Novartis AG Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 57. Novartis AG Recent Developments/Updates
    Table 58. Novartis AG Competitive Strengths & Weaknesses
    Table 59. Pfizer Inc. Basic Information, Area Served and Competitors
    Table 60. Pfizer Inc. Major Business
    Table 61. Pfizer Inc. Systemic Scleroderma Treatment Product and Services
    Table 62. Pfizer Inc. Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 63. Pfizer Inc. Recent Developments/Updates
    Table 64. Bayer AG Basic Information, Area Served and Competitors
    Table 65. Bayer AG Major Business
    Table 66. Bayer AG Systemic Scleroderma Treatment Product and Services
    Table 67. Bayer AG Systemic Scleroderma Treatment Revenue, Gross Margin and Market Share (2019-2024) & (USD Million)
    Table 68. Global Key Players of Systemic Scleroderma Treatment Upstream (Raw Materials)
    Table 69. Systemic Scleroderma Treatment Typical Customers
List of Figure
    Figure 1. Systemic Scleroderma Treatment Picture
    Figure 2. World Systemic Scleroderma Treatment Total Market Size: 2019 & 2023 & 2030, (USD Million)
    Figure 3. World Systemic Scleroderma Treatment Total Market Size (2019-2030) & (USD Million)
    Figure 4. World Systemic Scleroderma Treatment Revenue Market Share by Region (2019, 2023 and 2030) & (USD Million) , (by Headquarter Location)
    Figure 5. World Systemic Scleroderma Treatment Revenue Market Share by Region (2019-2030), (by Headquarter Location)
    Figure 6. United States Based Company Systemic Scleroderma Treatment Revenue (2019-2030) & (USD Million)
    Figure 7. China Based Company Systemic Scleroderma Treatment Revenue (2019-2030) & (USD Million)
    Figure 8. Europe Based Company Systemic Scleroderma Treatment Revenue (2019-2030) & (USD Million)
    Figure 9. Japan Based Company Systemic Scleroderma Treatment Revenue (2019-2030) & (USD Million)
    Figure 10. South Korea Based Company Systemic Scleroderma Treatment Revenue (2019-2030) & (USD Million)
    Figure 11. ASEAN Based Company Systemic Scleroderma Treatment Revenue (2019-2030) & (USD Million)
    Figure 12. India Based Company Systemic Scleroderma Treatment Revenue (2019-2030) & (USD Million)
    Figure 13. Systemic Scleroderma Treatment Market Drivers
    Figure 14. Factors Affecting Demand
    Figure 15. World Systemic Scleroderma Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 16. World Systemic Scleroderma Treatment Consumption Value Market Share by Region (2019-2030)
    Figure 17. United States Systemic Scleroderma Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 18. China Systemic Scleroderma Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 19. Europe Systemic Scleroderma Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 20. Japan Systemic Scleroderma Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 21. South Korea Systemic Scleroderma Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 22. ASEAN Systemic Scleroderma Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 23. India Systemic Scleroderma Treatment Consumption Value (2019-2030) & (USD Million)
    Figure 24. Producer Shipments of Systemic Scleroderma Treatment by Player Revenue ($MM) and Market Share (%): 2023
    Figure 25. Global Four-firm Concentration Ratios (CR4) for Systemic Scleroderma Treatment Markets in 2023
    Figure 26. Global Four-firm Concentration Ratios (CR8) for Systemic Scleroderma Treatment Markets in 2023
    Figure 27. United States VS China: Systemic Scleroderma Treatment Revenue Market Share Comparison (2019 & 2023 & 2030)
    Figure 28. United States VS China: Systemic Scleroderma Treatment Consumption Value Market Share Comparison (2019 & 2023 & 2030)
    Figure 29. World Systemic Scleroderma Treatment Market Size by Type, (USD Million), 2019 & 2023 & 2030
    Figure 30. World Systemic Scleroderma Treatment Market Size Market Share by Type in 2023
    Figure 31. Immunosuppressors
    Figure 32. Phosphodiesterase 5 inhibitors - PHA
    Figure 33. Endothelin Receptor Antagonists
    Figure 34. Prostacyclin Analogues
    Figure 35. Calcium Channel Blockers
    Figure 36. Others
    Figure 37. World Systemic Scleroderma Treatment Market Size Market Share by Type (2019-2030)
    Figure 38. World Systemic Scleroderma Treatment Market Size by Application, (USD Million), 2019 & 2023 & 2030
    Figure 39. World Systemic Scleroderma Treatment Market Size Market Share by Application in 2023
    Figure 40. Hospital
    Figure 41. Clinics
    Figure 42. Others
    Figure 43. Systemic Scleroderma Treatment Industrial Chain
    Figure 44. Methodology
    Figure 45. Research Process and Data Source

Companies Mentioned

Boehringer Ingelheim International GmbH
Gilead Sciences Inc.
GlaxoSmithKline plc
Novartis AG
Pfizer Inc.
Bayer AG